Viking Therapeutics (VKTX) Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/9/2026

1. TTAN
2. BRZE
3. CHYM
4. USO
5. QCOM
6. IRT
7. ASO
8. EVMN
9. AAPL
10. DYN

Go back to Viking Therapeutics (VKTX) Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Viking Therapeutic (VKTX) PT Raised to $80 at Stifel, '“Best-in-Class” Profile of Injectable VK2735 Stands Firm'

February 27, 2024 12:06 PM EST

Stifel analyst Samimy Annabel raised the price target on Viking Therapeutic (NASDAQ: VKTX) to $80.00 (from $35.00) while maintaining a Buy rating.

The analyst comments "Ahead of schedule, VKTX released the Ph.2 VENTURE data for injectable-VK2735, which again demonstrated a highly competitive profile relative to... More

Viking Therapeutics (VKTX) stock surges after phase 2 Venture trial meets primary and secondary endpoints

February 27, 2024 8:40 AM EST

Viking Therapeutics (NASDAQ: VKTX) shares surged more than 80% premarket Monday after the company announced positive top-line results from its Phase 2 clinical trial of VK2735.

VK2735 is a medicine that may help treat obesity and other metabolic disorders. It works by targeting to... More

Viking Therapeutic's (VKTX) Obesity Data Seen as 'Impressive'

February 27, 2024 7:55 AM EST

Truist Securities analyst Joon Lee commented on Viking Therapeutic (NASDAQ: VKTX) following the release of positive top-line results from Phase 2 VENTURE trial of its dual GLP-1/GIP receptor agonist VK2735 in patients with obesity. The study achieved its primary and all secondary endpoints, demonstrating... More